<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <title>Tzu-Hao (Steven) Liu – Portfolio</title>
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <style>
    body {
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      max-width: 900px;
      margin: 0 auto;
      padding: 24px 16px 48px;
      line-height: 1.6;
      background: #0b0b0b;
      color: #f5f5f5;
    }
    h1, h2, h3 {
      margin-top: 1.5em;
      margin-bottom: 0.5em;
    }
    h1 { font-size: 2rem; }
    h2 { font-size: 1.5rem; border-bottom: 1px solid #444; padding-bottom: 4px; }
    h3 { font-size: 1.15rem; }
    a { color: #6bb4ff; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .tagline { margin-top: 0.5em; font-size: 1rem; color: #cccccc; }
    .section { margin-top: 2rem; }
    ul { padding-left: 1.2rem; }
    .pill {
      display: inline-block;
      border-radius: 999px;
      padding: 2px 10px;
      border: 1px solid #444;
      font-size: 0.75rem;
      text-transform: uppercase;
      letter-spacing: 0.06em;
      color: #bbbbbb;
      margin-top: 4px;
    }
  </style>
</head>
<body>
  <header>
    <h1>Tzu-Hao (Steven) Liu</h1>
    <p class="tagline">
      Oncology-focused scientist specializing in small-molecule drug discovery and translational cancer biology.
    </p>
    <p>
      Email: <a href="mailto:tzuhao.steven.liu@gmail.com">YOUR_EMAIL_HERE</a> ·
      LinkedIn: <a href="https://www.linkedin.com/in/tzu-hao-liu" target="_blank">LinkedIn Profile</a>
    </p>
  </header>

  <section class="section" id="about">
    <h2>About</h2>
    <p>
      I am an oncology-focused scientist and Ph.D. candidate in Biomedical Sciences, specializing in small-molecule
      drug discovery and translational cancer biology. I drive oncology projects from target validation to preclinical
      candidate evaluation using cell-based, antibody-based, and biochemical assays, and integrate data-driven analysis
      to generate clear, decision-ready insights for therapeutic development.
    </p>
  </section>

  <section class="section" id="highlights">
    <h2>Research Highlights</h2>

    <h3>1. Target Validation</h3>
    <span class="pill">Antibody-based &amp; Biochemical Assays</span>
    <ul>
      <li>Metabolic Response (HPG) and Immune Response Detection (ELISA).</li>
      <li>Immunostaining and Proximity Ligation Assay.</li>
      <li>Quantitative Biomolecular Analysis by Immunoblotting and qPCR.</li>
    </ul>

    <h3>2. Preclinical Candidate Evaluation (Cell-based Assays)</h3>
    <ul>
      <li>Scratch Wound Healing Assay for Cell Migration.</li>
      <li>Dose–Response Cell Viability Assays and EC50/IC50 Determination.</li>
      <li>Clonogenic Survival and Long-term Colony Formation under Degrader Treatment.</li>
    </ul>

    <h3>3. Translational Oncology &amp; Data-driven Analysis</h3>
    <ul>
      <li>Volcano Plot of Differential Gene Expression after Treatment.</li>
      <li>RNA-seq Analysis Revealing Pathway-level Responses to Treatment (Bioinformatics Analysis).</li>
      <li>UMAP Embedding Revealing Treatment-induced Sample Clusters (Bioinformatics Analysis).</li>
    </ul>
  </section>

  <section class="section" id="publications">
    <h2>Publications, Manuscripts &amp; Patent</h2>
    <ul>
      <li>
        Liu, T.-H. †, Lyu, K. †, Zhao, J. C., Dang, X., Wang, X.*, &amp; Ji, J.-Y.*.
        <em>Development of potent and selective PROTAC degraders targeting transcriptional CDKs.</em>
        (Manuscript in preparation)
      </li>
      <li>
        Liu, T.-H. †, Li, X. †, Hsu, F. N. †, Sun, J., Niu, Y., Xing, Y., Liu, M., Liu, Y., Hemba-Waduge, R. U., Ni, J.-Q.*, &amp; Ji, J.-Y.*.
        <em>Asymmetric interdependency among the four subunits of the CDK8 module.</em>
        (Manuscript in preparation)
      </li>
      <li>
        Li, X., Liu, M., Xing, Y., Niu, Y., Liu, T.-H., Sun, J. L., Liu, Y., Hemba-Waduge, R. U., &amp; Ji, J.-Y*. (2024).
        <em>Distinct effects of CDK8 module subunits on cellular growth and proliferation in Drosophila.</em>
        Development 151(23): dev203111.
      </li>
      <li>
        Liu, M. †, Hemba-Waduge, R. U. †, Li, X., Huang, X., Liu, T.-H., Han, X., Wang, Y., &amp; Ji, J.-Y*. (2024).
        <em>Wnt/Wingless signaling promotes lipid mobilization through signal-induced transcriptional repression.</em>
        Proc Natl Acad Sci U S A 121(28): e2322066121.
      </li>
      <li>
        Li, X., Zhang, M., Liu, M., Liu, T.-H., Hemba-Waduge, R. U., &amp; Ji, J.-Y*. (2022).
        <em>Cdk8 attenuates lipogenesis by inhibiting SREBP-dependent transcription in Drosophila.</em>
        Dis Model Mech 15(11): dmm049650.
      </li>
      <li>
        <strong>Patent (provisional, in preparation)</strong> – Selective PROTAC degraders targeting transcriptional CDKs and their use in cancer therapy. Role: co-inventor.
      </li>
    </ul>
  </section>

  <section class="section" id="contact">
    <h2>Contact</h2>
    <p>
      For opportunities in translational oncology and small-molecule drug discovery, please feel free to contact me at
      <a href="mailto:YOUR_EMAIL_HERE">YOUR_EMAIL_HERE</a>.
    </p>
  </section>
</body>
</html>
